Initiator Pharma A/S (ST:INIT) — Market Cap & Net Worth
Market Cap & Net Worth: Initiator Pharma A/S (INIT)
Initiator Pharma A/S (ST:INIT) has a market capitalization of $24.16 Million (Skr224.53 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #24438 globally and #481 in its home market, demonstrating a 2.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Initiator Pharma A/S's stock price Skr3.28 by its total outstanding shares 68452892 (68.45 Million). Analyse Initiator Pharma A/S cash conversion from operations to see how efficiently the company converts income to cash.
Initiator Pharma A/S Market Cap History: 2017 to 2026
Initiator Pharma A/S's market capitalization history from 2017 to 2026. Data shows change from $16.41 Million to $24.16 Million (-3.37% CAGR).
Index Memberships
Initiator Pharma A/S is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.16% | #98 of 281 |
Weight: Initiator Pharma A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Initiator Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Initiator Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INIT by Market Capitalization
Companies near Initiator Pharma A/S in the global market cap rankings as of May 4, 2026.
Key companies related to Initiator Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Initiator Pharma A/S Historical Marketcap From 2017 to 2026
Between 2017 and today, Initiator Pharma A/S's market cap moved from $16.41 Million to $ 24.16 Million, with a yearly change of -3.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr24.16 Million | +10.81% |
| 2025 | Skr21.81 Million | -56.79% |
| 2024 | Skr50.46 Million | -25.87% |
| 2023 | Skr68.07 Million | +52.48% |
| 2022 | Skr44.64 Million | -25.55% |
| 2021 | Skr59.96 Million | +82.29% |
| 2020 | Skr32.90 Million | -39.55% |
| 2019 | Skr54.42 Million | +175.43% |
| 2018 | Skr19.76 Million | +20.42% |
| 2017 | Skr16.41 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Initiator Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.16 Million USD |
| MoneyControl | $24.16 Million USD |
| MarketWatch | $24.16 Million USD |
| marketcap.company | $24.16 Million USD |
| Reuters | $24.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more